Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Abbott Laboratories (NY:ABT)

136.01 +1.63 (+1.21%)
Official Closing Price Updated: 4:10 PM EDT, Jun 30, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Abbott Laboratories

< Previous 1 2
...
5 6 7 8 9 10 11 12 13
...
40 41 Next >
Healthcare Stocks Are Coming On Strong In July Led By Biotech
The biotech rally gained momentum in July with rotation out of technology stocks. 
Via Talk Markets
Why Is NLS Pharmaceutics (NLSP) Stock Up 48% Today?
NLS Pharmaceutics stock is up on Monday after the company provided NLSP investors with details on a merger deal with Kadimastem. 
Via InvestorPlace
Why Is Cognition Therapeutics (CGTX) Stock Down 33% Today?
Cognition Therapeutics stock is down on Monday after CGTX investors read the latest data from a Phase 2 clinical trial report. 
Via InvestorPlace
Abbott Labs (ABT) Stock Falls on Baby Formula Ruling. What to Know.
ABT stock is in focus on ruling news. Abbott faced a suit last year over the closing of its Michigan plant resulting in a formula shortage. 
Via InvestorPlace
3 High-Yield Dividend Stocks That Are Looking Super Hot
Discover high-yield dividend stocks offering solid returns. Learn about AbbVie, Target, and Abbott for reliable income and growth potential. 
Via InvestorPlace
Abbott, Integra LifeSciences And Other Big Stocks Moving Lower In Monday's Pre-Market Session
Via Benzinga
Abbott Laboratories's Options Frenzy: What You Need to Know
Via Benzinga
Peering Into Abbott Laboratories's Recent Short Interest
Via Benzinga
US Stocks Look To Extend Gains Ahead Of Key Tech Earnings, FOMC Meeting: Analyst Says This 'Could Serve As A Fundamental Catalyst For Small And Mid-Cap'
Index futures trading indicates cautious optimism as traders anticipate a busy week, with a slew of earnings reports, the two-day Federal Open Market Committee meeting starting Tuesday, and Friday’s... 
Via Benzinga
Abbott Laboratories Tumble Nearly 8% In Pre-Market After US Jury Charges $495M Penalty For Disease Causing Baby Formula
This verdict is part of nearly 1,000 lawsuits filed against Abbott Labs, its British rival Reckitt Benckiser, or both, in U.S. federal or state courts. 
Via Benzinga
Topics Lawsuit
Is Beaten-Down Dexcom Stock a Buy on the Dip?
The market may have overreacted to a disappointing earnings report. 
Via The Motley Fool
Why Pitney Bowes Shares Are Trading Higher By Over 12%; Here Are 20 Stocks Moving Premarket
Via Benzinga
Behind the Scenes of Abbott Laboratories's Latest Options Trends
Via Benzinga
Abbott Laboratories Earnings Top Views, Full-Year Guidance Raised
The drugmaker slightly topped profit and sales forecasts. 
Via Investor's Business Daily
Dexcom (DXCM) Stock Is Plunging on an ‘Execution Miss.’ What Is Really Going On?
Dexcom's Stelo faces an uncertain future thanks to drugs like Wegovy and a competing Abbott Labs product. DXCM stock is down 40% today. 
Via InvestorPlace
Better Buy: Abbott Laboratories vs. Intuitive Surgical
The medical technology business has been good for both companies, but which is right for your portfolio? 
Via The Motley Fool
3 High-Yielding Dividend Stocks That Can Help Bankroll Your Retirement Years
These stocks provide good yields and they don't come with much risk. 
Via The Motley Fool
Topics Retirement
7 Trustworthy Dividend Stocks to Steadily Build Your Portfolio
With political rumblings poised to make things exciting, investors may turn to the stability of trustworthy dividend stocks. 
Via InvestorPlace
AbbVie Could Soar 24%, According to a Wall Street Analyst. Is the High-Yield Dividend Stock a Buy Now?
The big pharma company's top drug is losing ground, but its dividend keeps rising. 
Via The Motley Fool
10 Best Dividend Growth Stocks to Buy and Hold Forever
Discover 10 dividend growth powerhouses that could turbocharge your portfolio's long-term performance. 
Via The Motley Fool
Stock Market Rotation Gets Rough; ASML, Eli Lilly, CrowdStrike, UnitedHealth In Focus: Weekly Review
The Nasdaq tumbled amid chip woes. 
Via Investor's Business Daily
Abbott Labs Makes Marketing Push For New Glucose Monitors, Targets Health-Conscious Consumers
Abbott Laboratories is launching Lingo, an over-the-counter glucose monitoring device aimed at non-diabetic consumers, utilizing TV and guerilla marketing. CEO Robert Ford expects Lingo to become a... 
Via Benzinga
Dow Plunges Over 500 Points Following Unexpected Surge In US Jobless Claims
The CNN Money Fear and Greed index showed a decline in the overall market sentiment, while the index moved to the "Neutral" zone on Thursday. 
Via Benzinga
Topics Stocks
7 Safe Stocks to Buy for Volatility Insurance
Although not known for their riveting narratives, these safe stocks to buy can offer protection amid a growth-sector shakedown. 
Via InvestorPlace
Abbott Laboratories (ABT) Q2 2024 Earnings Call Transcript
ABT earnings call for the period ending June 30, 2024. 
Via The Motley Fool
Topics Earnings
Why Are Abbott Laboratories Shares Trading Lower?
Shares of Abbott Laboratories (NYSE: ABT) are trading lower on Thursday following the company's announcement of its second-quarter 2024 financial results. 
Via Benzinga
Nasdaq Down Over 100 Points; Abbott Laboratories Earnings Beat Views
Via Benzinga
Topics Earnings
VIX Stages Double-Digit Spike As Risk Off Takes Over; Chipmakers Fail To Rebound, Weight Loss Giants Eli Lilly, Novo Tumble: What's Driving Markets Thursday?
It’s another risk-off day on Wall Street, with all major U.S. indices trading in the red. The CBOE Volatility Index (VIX), often referred to as the market’s fear gauge, spiked over 10%, reaching levels... 
Via Benzinga
Topics Stocks
ABT Stock Earnings: Abbott Laboratories Beats EPS, Beats Revenue for Q2 2024
ABT stock results show that Abbott Laboratories beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024. 
Via InvestorPlace
Abbott Laboratories Q2 Earnings: Revenue And Profit Beat Estimates, Nudges Up Annual Profit Guidance On Strong Medical Devices Growth
Abbott Laboratories reported Q2 sales of $10.38 billion, driven by 10.2% growth in Medical Devices, beating EPS estimates with $1.14 per share. Key highlights include FDA approval for two glucose... 
Via Benzinga
< Previous 1 2
...
5 6 7 8 9 10 11 12 13
...
40 41 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.